SMALL MOLECULE INJECTABLE DRUGS MARKET ANALYSIS

Small Molecule Injectable Drugs Market, By Drug Class (Small Molecule Antibiotics, Chemotherapy Agents, Skeletal Muscle Relaxants, Analgesics, Anticoagulants, Anticonvulsants, Antivirals, and Others), By Indication (Oncology, Pain Management, Cardiovascular Diseases, Infectious Diseases, CNS Diseases, and Others), By Mode of Delivery (Intravenous, Intramuscular, and Subcutaneous), By End User (Hospitals, Ambulatory Clinics, Outpatient Facility, Infusion Therapy Center, and Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

On September 17, 2024, Ascletis Pharma Inc., a pharmaceutical company, announced that it has completed the initial dosing in its two newly launched U.S. Phase I clinical trials for ASC30. This drug is notable for being the first and only small molecule GLP-1 receptor (GLP-1R) agonist capable of being administered both as a once-monthly subcutaneous injection and a once-daily oral tablet for obesity treatment
On May 7, 2024, Enable Injections, Inc., a leader in wearable drug delivery device technology, announced a partnership with F. Hoffmann-La Roche Ltd, a biotechnology company, to leverage Enable’s enFuse delivery technology for specific Roche development programs. This collaboration grants Roche a worldwide, exclusive license to develop and commercialize combinations of enFuse technology with select Roche molecules. The enFuse device is the first purely mechanical wearable system designed for subcutaneous delivery of large volumes of small molecule and biologic medications, allowing patients to receive treatment through a simple under-the-skin injection rather than intravenously.
In July 2021, Regeneron Pharmaceuticals, Inc., a global pharmaceutical company, and AstraZeneca, a biopharmaceutical company, announced a collaboration to research, develop, and commercialize small molecule compounds targeting the GPR75 receptor. This partnership aims to explore potential treatments for obesity and its related co-morbidities.